Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of anti-infection biotech Inhibitex (NAS: INHX) seem immune to today's general market malaise, jumping as much as 12.9% in pretty heavy trading.
So what: A Reuters report written in German reminded investors this morning that Swiss pharma giant Roche just might be interested in buying the company for about $2 billion. The gains quickly subsided when everyone realized that Reuters was simply reporting on rumors from earlier this week, which so far haven't led to any actual buyout offers.
Now what: And so the rumor mill reinforces itself like an echo chamber. That said, an Inhibitex buyout isn't out of the question as larger rival Pharmasset (NAS: VRUS) is getting swallowed by Gilead Sciences (NAS: GILD) in an $11 billion blockbuster deal. Antivirals are a hot property, and Inhibitex has its fair share of good-looking drug candidates in the pipeline.
Interested in more info about Inhibitex? Click here to add it to My Watchlist.
At the time thisarticle was published Fool contributor Anders Bylund holds no position in any of the companies mentioned. Motley Fool newsletter services have recommended buying shares of Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinion, but we all believe that considering a diverse range of insights makes us better investors. Check out Anders' holdings and bio, or follow him on Twitter and Google+. We have a disclosure policy.
Copyright © 1995 - 2011 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.